Author: acn

HONG KONG, Feb 25, 2026 - (ACN Newswire via SeaPRwire.com) – Shoucheng Holdings Ltd. (00697.HK) drew market attention on Tuesday after its share price experienced volatility alongside certain shareholding adjustments, prompting discussion among investors. A review of the company’s recent disclosures, publicly available trading data and evolving market structure suggests the movement largely reflects short-term capital repositioning rather than any change in fundamentals.Market participants indicated that during the recent market pullback, several international long-only investors executed strategic allocations through block trades and negotiated transactions, facilitating an orderly transition in the company’s shareholder base. Observers said the shift — characterized by a rotation from short-term trading positions to longer-duration institutional capital — could help smooth liquidity fluctuations while enhancing the stability and quality of the shareholder structure.From a capital-markets perspective, the entry of long-term funds typically signals recognition of a company’s medium- to long-term growth trajectory and value realization capacity. Such positioning is widely viewed as laying a firmer foundation for future valuation normalization.Historically, shareholder base optimization and rebalancing often coincide with the stage at which a company’s strategic transformation begins to translate into tangible results. The latest restructuring underscores a more proactive stance by international capital in participating in Shoucheng’s growth story, endorsing its strategic shift from a traditional asset-management platform to a builder of hard-technology industrial ecosystems. The resonance between capital flows and industrial logic is expected to reinforce market confidence in the company’s long-term value proposition.Foreign institutional buying during periods of market weakness reflects confidence in what analysts describe as a structural transformation of Shoucheng’s fundamentals. The company has transitioned from a conventional asset-management model into what it terms an “industrial ecosystem builder.” Through a differentiated “capital + scenario + operations” framework, Shoucheng has established a closed-loop ecosystem, particularly in the robotics sector, where its forward-looking investments have positioned it as a bellwether for hard-technology exposure in Hong Kong equities.The year 2026 is widely regarded by the market as a pivotal window for the accelerated commercialization of embodied artificial intelligence and humanoid robotics. Shoucheng’s systematic early-stage positioning across the robotics value chain is now entering a concentrated realization phase, with portfolio returns demonstrating notable strength.Core projects have generated substantial premiums. Early and concentrated investments in leading companies such as Zibianliang Technology and Unitree Robotics have delivered significant mark-to-market gains. As high-profile holdings including Unitree advance toward initial public offerings, Shoucheng’s equity stakes are poised to transition from unrealized book gains to realized returns and dividend contributions, providing tangible earnings accretion at the listed-company level.Further attention has focused on the high-profile appearance of robotics firms including Unitree Robotics, Galaxy General Robotics and Songyan Dynamics at the 2026 Lunar New Year Gala broadcast by China Central Television, the Year of the Horse edition. Their demonstrations showcased breakthroughs in embodied intelligence, complex motion control and human-machine interaction. The visibility not only strengthened public awareness but also signaled that large-scale commercial deployment may be imminent. As an important early-stage investor in these enterprises, Shoucheng stands to benefit indirectly from both heightened sector visibility and an accelerated commercialization cycle, potentially catalyzing valuation re-rating.Analysts said Tuesday’s trading activity is likely to result in a more diversified shareholder mix. The participation of long-duration international capital may enhance the stock’s global liquidity profile and governance transparency expectations, while also broadening the company’s access to cross-border industrial and strategic resources to support future expansion.Market experience suggests that when a company’s fundamentals enter an upward cycle and structural uncertainties gradually dissipate, shareholder optimization can serve as a catalyst for valuation recovery. According to analysts, the latest rotation in holdings represents a strategic rebalancing of the capital structure, easing short-term supply pressure as the company approaches a value-realization phase.Taken together, Shoucheng appears to be navigating a convergence of three inflection points. First is an industrial inflection, as embodied AI and robotics commercialization accelerate. Second is a capital inflection, with investment projects entering a concentrated realization period. Third is a structural inflection, marked by the entry of long-term international capital and the optimization of the shareholder base.Amid the alignment of global capital endorsement and industrial value dividends, the company’s valuation framework is shifting from that of a traditional asset manager toward that of a hard-technology industrial platform. As industrial deployment advances and investment returns crystallize, market recognition of Shoucheng’s role as an infrastructure builder for the intelligent era may deepen, suggesting that the process of long-term value redefinition has entered a substantive phase. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亞太商訊 via SeaPRwire.com) - 2月23日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」或「公司」，股份代號：1788.HK））宣布，已正式獲得香港證券及期貨事務監察委員會（SFC）批准，自2026年2月12日起可在其兩家持牌機構（國泰君安證券（香港）有限公司及國泰君安外匯有限公司）采用國際掉期與衍生工具協會ISDA標準初始保證金模型（Standard Initial Margin Model, "SIMM" ）計算場外衍生品交易的初始保證金。ISDA SIMM 是業界通用的標準方法論，專門用于計算非集中清算衍生品的監管初始保證金。該模型通過建立統一的計算標準，使所有市場參與者得以遵循同一框架進行保證金核算，不僅避免了各機構獨立開發模型所産生的額外成本，還有效减少了因算法差异引發的潜在爭議。其配套的治理框架進一步確立了行業共同實踐，確保保證金計提既符合全球監管要求，又充分保障了保證金的充足性。此次獲批標志著國泰君安國際場外衍生品業務的風險管理能力邁上新台階，在鞏固合規與風控標杆的同時，顯著提升中資券商國際化競爭力。通過采用國際市場通行的SIMM模型，公司得以接軌國際大行標準，能够更精准、高效地管理初始保證金，在有效控制交易對手風險的同時，顯著節省交易成本，實現更高資本效率，增强與全球機構對手方的合作信任，從而提升業務的長期競爭力。此次獲批不僅是對公司衍生品業務技術實力的認可，更是監管機構對公司內部控制、尤其是風險管理能力的又一里程碑式肯定。展望未來，國泰君安國際將進一步精進衍生品業務的內控管理體系，築牢長遠穩定發展的根基。同時，作爲香港資本市場的重要一員，公司將一如既往地配合監管機構，深度參與市場基礎設施建設，助力提升香港場外衍生工具市場的國際競爭力與活力。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK）,是中國證券公司國際化的先行者和引領者，公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高品質、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司 （「康哲藥業」）欣然宣佈，旗下德鎂醫藥有限公司（「德鎂醫藥」，專業聚焦皮膚健康的創新型醫藥企業，正申請於香港聯合交易所有限公司主板獨立上市，詳見康哲藥業日期為2025年4月22日發佈的公告）已於2026年2月24日獲得中國國家藥品監督管理局（NMPA）受理磷酸蘆可替尼乳膏（「產品」）輕中度特應性皮炎（「AD」）的新藥上市許可申請（NDA）。產品擬用於其他外用藥控制不佳或不建議使用時，非免疫功能受損的2歲及以上兒童和成人輕中度特應性皮炎的局部短期和非持續性慢性治療。且該項NDA因「符合兒童生理特徵的兒童用藥品新品種、劑型和規格」，已獲得NMPA藥品審評中心批准納入優先審評品種名單，有望加快產品AD適應症上市審評進程。特應性皮炎III期臨床數據亮眼，優先審評加速上市磷酸蘆可替尼乳膏已於2026年1月獲得NMPA批准上市，成爲中國批准的首款且唯一用於白癜風治療的靶向藥。此次增加AD適應症NDA獲受理，是產品向多治療領域拓展的關鍵里程碑。磷酸蘆可替尼乳膏已在輕中度AD的一項隨機、雙盲、安慰劑對照中國三期藥物臨床研究取得積極結果：- 療效優異：產品成功達到主要終點，即使用產品治療8周，達到研究者整體評估（IGA）評分為0或1分，且較基線改善≥2分的受試者比例，顯著高於安慰劑（63.0% vs 9.2%，P

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 康希諾生物（688185.SH/06185.HK）宣佈，公司自主研發的ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）——曼海欣(R)擴大適用人群的補充申請已正式獲得國家藥品監督管理局批准。此次獲批後，曼海欣(R)適用於3月齡至6周歲（83月齡）的嬰幼兒及兒童，用於預防由A、C、Y、W135群腦膜炎奈瑟菌引起的流行性腦脊髓膜炎（以下簡稱"流腦"）。此次曼海欣(R)擴齡獲批，具有重要的公共衛生和商業發展意義。一方面，在我國現行免疫規劃程式中，6歲是入學前流腦疫苗接種"最後一針"的重要節點，長期以來，國內針對3歲以上兒童的多價流腦結合疫苗選擇相對有限。曼海欣(R)此次擴齡獲批，為學齡期兒童提供了四價流腦多糖結合疫苗接種選擇，有助於填補兒童流腦防控在關鍵年齡階段的保護空白，進一步完善我國流腦免疫屏障。另一方面，適用人群範圍的擴大，將有助於曼海欣(R)進一步釋放產品潛力，提升商業化空間，並為該產品在國際市場的推廣與佈局奠定更為堅實的基礎。值得一提的是，康希諾生物日前已發佈2025年度業績預告，全年營收預計10.4–10.8億元，同比增長22.88%-27.61%；歸母淨利潤預計2450萬–2900萬元，將實現扭虧為盈。同時，公告明確指出，"公司持續踐行以創新為核心、以商業化落地為重點的發展戰略，中國首款四價流腦結合疫苗曼海欣(R)收入保持持續增長"。這也意味著康希諾生物已進入創新疫苗商業化收穫期。依託獨家技術平台、領先優勢及加速的國際化佈局，曼海欣(R)擴齡不僅鞏固了市場競爭力，也為康希諾生物的可持續增長注入新的動力。隨著產品覆蓋和國際拓展的推進，公司長期價值將開啟更廣闊的發展空間。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) - 2026年2月22日, 納斯達克上市公司迦里仕人才集團有限公司（Galaxy Payroll Group Limited，NASDAQ: GLXG，以下簡稱「迦里仕人才」）今日宣布，已與耐吉中國控股香港有限公司澳門分公司（NIKE China Holding HK Limited (Macau Branch)，以下簡稱「耐吉澳門分公司」）正式續簽為期五年的戰略合作協議。合作再延五年，服務範圍全面覆蓋核心HR職能根據協議，雙方合作期限自2025年12月1日起至2030年11月30日止。在此期間，迦里仕人才將繼續為耐吉澳門分公司提供涵蓋本地薪資發放、考勤與休假管理、社保及稅務合規申報，以及勞動法規與用工政策咨詢在內的一站式人力資源外包服務。該合作模式有效支持耐吉澳門分公司聚焦其核心零售與品牌運營，提升整體組織效能。戰略續約彰顯客戶高度信任，強化收入穩定性此次續約不僅是雙方合作關系邁入新階段的重要標志，更體現了國際頭部品牌對迦里仕人才專業能力、合規水平及長期服務交付質量的高度認可。中長期合約的簽署顯著增強了公司未來五年收入的可預測性與現金流穩定性，進一步契合其打造高質量、抗周期業務模型的資本市場戰略。本地化能力構築核心壁壘，服務體系持續進化自2013年成立以來，迦里仕人才始終深耕港澳市場，並逐步拓展跨區域服務能力。公司憑借對香港及澳門勞動法、稅務及社保政策的深度掌握，建立起紮實的本地合規能力；同時依托標准化流程與定制化方案相結合的服務體系，確保交付的一致性與可擴展性。其自主開發的薪資與考勤管理平臺，在提升運營效率的同時有效保障數據安全與業務連續性，成為吸引並維系跨國企業客戶的關鍵優勢。在過往合作中，迦里仕人才已多次協助耐吉澳門分公司應對複雜用工環境下的合規挑戰，其解決方案在准確性、響應速度及風險控制方面均獲得充分驗證，為本次長期續約奠定了堅實基礎。展望未來：從服務交付邁向價值共創展望新合作周期，迦里仕人才將在現有服務框架基礎上，持續優化薪資管理流程與智能考勤系統，並通過數據整合與定期管理報表，助力客戶推進人力資源管理的規範化與數字化轉型。雙方亦約定保留通過補充協議靈活拓展服務範圍的機制，確保合作節奏與客戶業務發展動態同步。此次五年期戰略合作的續簽，不僅是對迦里仕人才專業價值的長期肯定，更是對其商業模式可持續性的有力印證。它將進一步鞏固公司在港澳及亞太人力資源外包市場的品牌影響力，並為服務更多跨國零售、體育及消費品牌提供可複制的標杆案例。在全球企業日益重視合規效率、成本優化與組織韌性的背景下，迦里仕人才正憑借其深厚的本地化經驗、穩健的服務體系與高粘性的優質客戶基礎，穩步構建長期增長動能。公司管理層表示：「我們將繼續以服務能力為核心驅動力，深化與現有優質客戶的戰略合作，同時積極拓展更多具有長期價值的跨國及區域性企業客戶，持續為股東創造穩健、可持續的回報。」 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) – 2026年新版《道路機動車輛生產企業准入審查要求》中，仿真驗證能力被作為強制性關鍵要素寫入准入審查要求，國產仿真平臺迎來巨大的市場利好，進一步推動了智駕產業鏈加速向「自主可控」邁進。在此背景下，五一視界宣布旗下51Sim下一代智駕仿真平臺 SimOne 4.0 已於近日成功完成在摩爾線程旗艦級AI訓推一體全功能GPU MTT S5000上的系統性適配與深度優化。從大模型感知挖掘、4DGS模型訓練到4DGS仿真推理和合成數據生成，雙方強強聯手，實現了國產算力與端到端智能駕駛仿真體系的完整打通，正式開啟了物理AI智駕領域高置信度閉環仿真與合成數據的全棧國產化新篇章,為應對新規下的嚴苛驗證需求提供了堅實的國產底座。算力底座的「跨代式」追趕隨著端到端智駕收斂到VLA和世界模型兩條路線，基於海量Log數據的高置信度閉環仿真和合成數據已成為提升算法長尾場景處理能力的關鍵命題。仿真效率的上限，往往取決於基礎一硬件的規格。在很長一段時間裏，高端GPU市場幾乎被海外巨頭壟斷，但五一視界與摩爾線程的最新合作成果顯示，這一格局正在發生微妙的變化。SimOne 4.0已完成與摩爾線程MTT S5000的深度適配。MTT S5000是專為大模型訓練、推理及高性能計算而設計的全功能GPU智算卡，基於第四代MUSA架構「平湖」打造。其單卡AI算力（稠密）最高可達1000 TFLOPS，配備80GB顯存，顯存帶寬達到1.6TB/s，卡間互聯帶寬為784GB/s，完整支持從FP8到FP64的全精度計算。基於SimOne 4.0實現7個周視攝像頭4DGS場景重建效果在實測數據中，MTT S5000展現出了足以抗衡甚至部分超越國際主流競品的硬實力。數據顯示，MTT S5000在FP32、FP16及INT8等關鍵精度上實現了約1.47倍的性能增長，FP64雙精度算力領先幅度約1.48倍。更值得關注的是其搭載的MTLink技術，使得卡間帶寬提升約30%。MTT S5000憑借FP8提升訓推效率、FP64保障計算精准、光線追蹤實現高保真渲染，以自主可控的強勁底層算力，為智能駕駛提供安全、高效、可靠的核心國產算力支撐。場景實測：在複雜博弈中驗證「真功夫」硬件參數的領先，最終需要在真實的算法場景中落地。在SimOne 4.0的大模型感知挖掘功能中，雙方針對Qwen3-VL多模態大模型進行了深度調優。實測結果令人驚喜：無論是在8B模型還是更複雜的30B MoE架構下，MTT S5000在「預填充（Prefill）」階段的首字響應速度（TTFT）均優於國際主流競品，優勢最高擴大至14%，且在10並發的高壓環境下依然保持了穩健的吞吐量。而在更考驗訓練和推理能力的4DGS（4D高斯潑濺）領域，基於51Sim入選AAAI 2026的LidarPainter技術，國產算力同樣經受住了考驗。目前測試數據顯示，在訓練端，MTT S5000展現出比肩國際主流競品的強勁性能，僅需2.5小時即可完成一個真實Clip場景的高質量重建；在推理端，面對單Clip包含1600萬個高斯點的超大模型負載，MTT S5000成功實現了11路攝像頭加1路激光雷達的實時閉環仿真，呈現出像素級的高保真效果。這證明了國產顯卡在處理複雜光影與動態物體還原時，已經具備了生產力級別的屬性,能夠勝任准入審查中要求的極端工況與邊界條件驗證。這種高保真物理場景的重建能力，同樣可遷移至具身智能機器人的空間感知與操作訓練中。基於LidarPainter 技術生成高真實度新視角圖像隱形護城河：構建「芯片+系統」的通用底座如果說高性能GPU的適配是攻克了「最難的骨頭」，那麼對國產基礎軟硬件生態的全面覆蓋，則是五一視界構築的一條安全護城河,也是響應國家信創戰略、滿足敏感行業准入要求的關鍵。除了圖形計算領域，五一視界已悄然完成了對主流國產芯片架構的全線互認。在CPU層面，無論是基於ARM架構的華為鯤鵬、飛騰，還是基於x86架構的海光、兆芯，五一視界旗下的51Aes、51Sim等核心產品均已實現流暢部署。特別是通過華為鯤鵬技術認證並加入「鯤鵬展翅」計劃，進一步夯實了其在國產服務器端的運行穩定性。在操作系統層面，為了徹底擺脫對非國產發行版的依賴，五一視界將適配工作下沉至系統內核，先後完成了與麒麟軟件（銀河麒麟高級服務器操作系統）及統信軟件（UOS）的適配認證。這一舉措意味著，對於政府、能源等有著嚴苛信創要求的敏感行業客戶而言，他們可以選擇從芯片到底層操作系統到上層應用全鏈路自主可控的數字孿生解決方案,從容應對日益嚴格的合規性審查,構建起一個不僅服務於智能駕駛，更能廣泛賦能於人形機器人等具身智能終端的國產化通用基礎設施。中國科技企業「國產自主可控」已經崛起從攜手摩爾線程在高端算力上撕開缺口，到打通華為鯤鵬、麒麟等操作系統的生態脈絡，再到積極響應新版准入審查要求提供合規的仿真驗證能力，五一視界的這一系列動作表明，中國企業的「國產自主可控」正在發生量變和質變，正在緩緩崛起。這不再是簡單的參數對標，而是產業生態的戰略閉環。SimOne 4.0的表現證明，國產軟硬件方案已經邁過了「能用」的門檻，正式進入了高精度、高負載任務的「好用」階段。隨著算法與算力的深度融合，以及政策法規對仿真驗證能力的強制加持，一個繁榮的、自主可控的物理AI生態底座正在逐步成型，為中國智能駕駛產業的獨立發展保駕護航,也為具身智能機器人等新興領域的國產化落地鋪平了道路。基於SimOne 4.0 的4DGS閉環仿真 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亞太商訊 via SeaPRwire.com) – 2月23日，由上海實業（集團）有限公司（以下簡稱「上實集團」）與國泰海通證券股份有限公司（以下簡稱「國泰海通」）聯合發起設立的滬港新興產業基石基金（以下簡稱「基石基金」）正式啟航，進入實質投資階段。作為全國首支、上海市級市場化運作的證券類港股基石基金，基金目標總規模30億港元，首期規模10億港元，將聚焦集成電路、生物醫藥、人工智能上海三大先導產業，專項支援優質企業赴港上市，深化滬港金融與產業協同。服務上海戰略，強化滬港聯動上海市政府和上海市國資委指導設立的基石基金，是上海國資服務上海科技創新中心建設、推動重點產業高質量發展的重要舉措，將緊密圍繞上海前瞻的集成電路、生物醫藥、人工智能三大先導產業進行戰略佈局，通過資本市場賦能，加速本地創新企業國際化進程。同時，基金也將充分發揮香港作為國際金融中心的樞紐功能，構建「上海產業+香港資本」的高效聯通機制，促進兩地金融資源互補與市場互聯，打造滬港合作新標杆。創新「雙管理人」架構，滙聚兩地專業力量基石基金在治理模式上採用創新的「雙管理人」架構，由上實集團在港金融投資業務平台上實資本（香港）投資管理有限公司，和國泰海通在港資產管理平台海通國際資產管理有限公司共同擔任基金管理人，並由滬港兩地協同運營。這一合作架構充分融合了上實集團作為上海在港窗口企業的產業資源與香港本地的運營優勢，及國泰海通在全球資本市場和跨境資產管理方面的專業能力，實現「產業+金融」、「上海+香港」的雙重優勢互補。通過建立完善的投資決策機制與風險控制體系，該架構既確保了基金運作符合國際標準，又保持了與本土產業生態的深度連結，為基金的長期穩健運作奠定了堅實基礎。多元化投資策略，專注長期價值基石基金堅持市場化、專業化、國際化運作原則，以產業、金融雙重視角，構建覆蓋企業全生命週期的投資與賦能體系。通過靈活的多元化策略組合與深度投後服務，系統性支援上海三大先導產業優質企業的業務發展與價值實現。基石基金在重點參與上海三大先導產業優質企業赴港IPO的基石投資之外，還可以參與港股IPO錨定和已上市港股的配售投資，通過無鎖定期策略保持基金的流動性，以保證基金投資收益；在市場大幅下跌時，也可通過二級市場方式，增持價值低估的優質公司股票；同時跟進優秀企業再融資及併購重組，助力可持續發展。基石基金將嚴格遵循「好賽道、好公司、好價格」的遴選標準，重點投向具備核心技術、高成長性和穩健現金流的行業領軍企業。強化上海國資在港功能，構建跨境投資新平台基石基金是上實集團和國泰海通強化在港服務功能、完善跨境投資佈局的關鍵舉措之一。基石基金不僅進一步完善上海國資基金矩陣，填補國資基金在港股IPO及二級市場策略的空白，服務上海企業赴港上市「最後一公里」融資需求，助力構建「早期投資—成長期融資—公開市場上市」的完整產業投資生態；更通過上實集團和國泰海通的深度合作，強強聯手、協作共贏，系統提升跨境合規、資產配置與複雜交易設計能力，進一步增強上海國資服務上海乃至國家戰略的綜合實力。展望：鏈接國際資本，賦能創新未來在全球科技創新競爭日益激烈的背景下，滬港新興產業基石基金的實質啟動，標誌著上海在對接國際資本市場、服務本土創新方面邁出系統性的一步。在人民幣國際化和「惠港五條」等政策紅利支持下，基石基金將成為連接內地產業資本與國際金融資源的重要紐帶。未來，基石基金將積極把握人民幣國際化與金融市場雙向開放機遇，持續促進國際資本投資上海核心產業，為上海三大先導產業企業提供全方位的資本服務，助力更多硬科技企業走向世界，為滬港融合與高質量發展貢獻力量。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - February 23, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company has entered into an advertising services agreement (the "Agreement") dated February 19, 2026 with AJO Capital Inc. ("AJO"), whereby AJO will provide marketing and investor awareness services to raise public awareness of GMG, including without limitation, original news articles, podcast and interview content creation, newspaper, television, radio and industry network distribution, as well as social media support (the "Services"). GMG has agreed to a monthly payment of US$26,500 for the provision by AJO of the Services. The Agreement commenced on February 19, 2026 and has an initial term of four (4) months unless earlier terminated. The Agreement may be renewed upon mutual written agreement at least thirty (30) days prior to the expiration of the initial term, subject to any modifications to compensation and payment terms as the parties may agree.AJO is a private company based in New York, United States dedicated to providing financial information and media and communication services. The Company will not issue any securities of the Company to AJO as compensation. To the Company's knowledge, AJO and its directors and officers are arm's length from the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, services to be provided by AJO, term and termination of the Agreement and compensation payable to AJO pursuant to the Agreement.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the services to be provided by AJO, covenants by AJO under the Agreement, length of the term of the Agreement, termination of the Agreement and compensation payable to AJO pursuant to the Agreement, that the Company will not issue any future securities to AJO as compensation under the Agreement, that AJO acts at arm's length to the Company and none of AJO, its directors nor officers have any direct or indirect interest in the Company and its securities nor do they have any right to acquire such interests. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, failure by AJO to render services in accordance with the Agreement, breach of the Agreement by either parties, early termination of the Agreement and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285033 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®.Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons."MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long-range weapons."So far, GA-ASI has performed all the performance analytics and is confident in MQ-9B's ability to carry long-range weapons over long distances, while providing a measure of persistence and endurance. Company engineers and others continue to refine the technical aspects of this integration and potential concepts of operation, eyeing weapons such as the Lockheed Martin Joint Air-to-Surface Standoff Missile andLong-Range Anti-Ship Missile, as well as the Kongsberg/Raytheon Joint Strike Missile.GA-ASI plans to fly at least one of these new weapons as early as 2026.Hypothetically, a mission profile might look like this: MQ-9Bs could launch from a number of friendly bases in the Western or Southern Pacific, fly to a hold point and loiter there outside a hostile power's weapons engagement zone. If the order came to release the weapons, the aircraft could launch them in coordination with other U.S. or allied operations.In addition to the SkyGuardian and SeaGuardian models, MQ-9B also includes the Protector RG Mk1 that is currently being delivered to the United Kingdom's Royal Air Force (RAF). GA-ASI also has MQ-9B procurement contracts with Belgium, Canada, Denmark, Germany, India, Japan, Poland, Taiwan and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also been featured in various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, RIMPAC, and Group Sail.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年2月23日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA-ASI）正為其頂級機型MQ-9B天衛者®與海衛者®開發遠程離場武器系統。海軍與空軍作戰人員持續要求具備遠距鎖定威脅目標的能力，尤其在西太平洋廣闊的海域與空域中。正因如此，通用原子航空系統公司（GA-ASI）工程師已著手調整MQ-9B的載荷、穩定性、航程等特性，以適應新一代遠程精確武器的需求。通用原子航空系統公司總裁大衛·R·亞歷山大表示：「MQ-9B在實戰中持續展現卓越性能，我們的全球客戶名單不斷擴增。我們期望透過拓展任務範疇持續提升該機型價值。MQ-9B具備非凡的載荷能力，因此增強其搭載遠程武器的能力以擴充任務組合，實屬必然之舉。」迄今，通用原子航空系統公司已完成所有性能分析，確信MQ-9B具備長距離攜帶遠程武器的能力，同時能維持持久作戰與耐力表現。公司工程師團隊正持續優化技術整合細節與潛在作戰概念，鎖定洛克希德·馬丁聯合空對地遠程巡弋飛彈、遠程反艦飛彈，以及康斯伯格/雷神聯合打擊飛彈等武器系統。通用原子航空系統公司計劃最早於2026年實現其中一種新型武器的實彈飛行測試。假設性任務流程可能如下：MQ-9B無人機可從西太平洋或南太平洋多個友軍基地起飛，飛抵預定待命點並在敵方武器射程外盤旋。若接獲發射指令，該機可協同美軍或盟軍作戰行動執行武器投放。除天衛者與海衛者型號外，MQ-9B系列還包含正交付英國皇家空軍的護衛者RG Mk1型號。通用原子航空系統公司亦與比利時、加拿大、丹麥、德國、印度、日本、波蘭、台灣及美國空軍簽訂MQ-9B採購合約，以支援特種作戰司令部任務。MQ-9B亦參與多項美國海軍演習，包括「北方邊緣」、「綜合戰鬥演習」、「環太平洋軍事演習」及「艦隊航行訓練」。關於通用航空系統公司通用原子航空系統公司是全球首屈一指的無人機系統（UAS）製造商。捕食者®系列無人機系統累積飛行時數逾900萬小時，服役超過30年，包含MQ-9A死神®、MQ-1C灰鷹®、MQ-20復仇者®以及MQ-9B天衛者®/海衛者®等機型。該公司致力提供具備持久任務能力的多任務解決方案，實現持續性戰場感知與快速打擊能力。欲了解更多資訊，請造訪 https://www.ga-asi.com。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 及 SkyGuardian 為通用原子航空系統公司之商標，於美國及其他國家註冊。GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc. ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms.The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands."We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to utilize onboard sensors to make independent decisions and execute commands from the F-22."The demonstration showcased Manned-Unmanned Teaming and rapid software integration between the MQ-20 and the F-22, and a tactical data link used for communication and coordination between military platforms. The MQ-20 successfully exchanged messages with the F-22, and the F-22 was able to send autonomy commands to the MQ-20 via the Autonodyne Bashi Pilot Vehicle Interface (PVI), directing the MQ-20 to execute tactical maneuvers and adjust waypoints, and perform Combat Air Patrol (CAP) and airborne threat engagement tasks.This demonstration highlighted the potential of CCAs to act as force multipliers for manned platforms, enabling collaboration between autonomous systems and human pilots. GA-ASI's MQ-20 Avenger unmanned jet has served as a surrogate CCA for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, MQ-9B SkyGuardian®/SeaGuardian®, XQ-67A, and YFQ-42A. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年2月23日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA-ASI）攜手美國空軍，於南加州愛德華茲空軍基地進行最新自主任務演示。此次演習運用MQ-20復仇者®無人噴射機，並搭配配備最新政府參考規格的F-22猛禽戰機，共同執行自主任務。(GA-ASI) 於南加州愛德華茲空軍基地，運用其MQ-20復仇者®無人戰機與搭載最新政府參考自主軟體的F-22猛禽戰機，執行自主任務進行最新技術展示。此次測試透過自主系統與戰術數據鏈的結合，實現F-22與MQ-20間的機人協同作戰，展現兩平台間的精準協調能力。任務包含MQ-20與F-22的實戰交戰演練--由機載人類飛行員駕駛的F-22擔任指揮機，此舉彰顯了接收並執行協同作戰指令的能力。通用原子航空系統公司總裁大衛·R·亞歷山大表示：「我們對本次任務運用政府先進自主系統的完美執行深表讚賞。此次演示不僅整合了任務要素，更展現自主系統運用機載感測器獨立決策，並執行F-22指令的能力。」此次演示展示了MQ-20與F-22之間的有人-無人協同作戰能力及快速軟體整合，並運用戰術數據鏈實現軍事平台間的通訊與協調。MQ-20成功與F-22交換訊息，並透過Autonodyne Bashi飛行器介面（PVI）接收F-22發出的自主指令，執行戰術機動、調整航點，並完成戰鬥空中巡邏（CAP）及空中威脅攔截任務。此次演示凸顯了戰鬥伴飛無人機作為有人平台戰力倍增器的潛力，實現了自主系統與人類飛行員的協同作戰。通用原子航空系統公司的MQ-20復仇者無人噴射機已作為戰鬥伴飛無人機的替代方案服役逾五年，其任務涵蓋該公司專門研發的XQ-67A與YFQ-42A機型問世前後的階段。關於通用原子航空系統公司通用原子航空系統公司是全球首屈一指的無人機系統製造商。捕食者®系列無人機系統累積飛行時數逾900萬小時，服役逾30年，包含MQ-9A死神®、MQ-1C灰鷹®、MQ-20復仇者®、MQ-9B天衛者®/海衛者®、XQ-67A及YFQ-42A等機型。該公司致力於提供具備持久任務能力的多任務解決方案，實現持續性態勢感知與快速打擊能力。更多資訊請造訪 www.ga-asi.com。復仇者、鷹眼、灰鷹、山貓、捕食者、死神、海衛士及天衛士均為通用原子航空系統公司之商標，於美國及其他國家註冊。通用原子航空系統公司媒體關係部General Atomics Aeronautical Systems, Inc. ASI-MediaRelations@ga-asi.com(858) 524-8101消息來源：通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BOSTON, MA, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran’s novel galectin antagonist as a potential therapeutic for infected poultry . The research is being led by Dr. Daniela Rajao DVM, MS, PhD, a renowned expert in virology and poultry medicine, College of Veterinary Medicine, Department of Population Health at UGA .Bioxytran’s drug candidate, PHM23, utilizes a novel mechanism of action that targets galectin proteins critical to viral replication. By blocking viral spike proteins from attaching to host cells, the therapy aims to neutralize the virus and halt its spread . In vitro studies have already demonstrated the molecule's effectiveness against viruses similar to H5N1, providing a strong foundation for this new research ."The initiation of this research with the University of Georgia, a world leader in poultry health, marks a significant milestone for Bioxytran," said David Platt, CEO of Bioxytran, Inc. "The ongoing H5N1 outbreaks present a urgent threat to the global food supply and economy, requiring immediate mass culling that results in billions of dollars in losses. We believe our galectin antagonist technology offers a promising path forward—not just for containment, but for a humane and sustainable solution to protect animal health."The potential of this research has already garnered significant academic recognition. Following the establishment of the collaboration, UGA selected PHM23 as one of a handful of molecules to be featured in its grant submission to the U.S. Department of Agriculture’s (USDA) prestigious $100 million HPAI Poultry Innovation Grand Challenge . This inclusion underscores the scientific promise of Bioxytran’s platform in addressing one of agriculture's most pressing challenges.Current protocols for managing bird flu outbreaks often necessitate the culling of entire flocks to prevent the virus's spread. Bioxytran’s approach could offer a more effective alternative, enable rapid containment of the virus and mitigate the devastating economic impact on farmers and consumers .Bioxytran is actively seeking further partnerships with academic, industry, and government stakeholders to accelerate the development and deployment of PHM23 in response to this urgent global need .About Bioxytran, Inc. Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in virology, cancer metastasis, and oxygen transport. Its leading antiviral platform utilizes galectin antagonists to combat viral diseases. For more information, visit www.bioxytraninc.comAbout University of Georgia The University of Georgia is a land-grant and sea-grant university with a worldwide reputation for its expertise in poultry science and veterinary medicine. Its College of Veterinary Medicine and related research institutes are leaders in combating animal diseases that threaten the food supply.Investor Relations Contact: David Platt, PhD/CEO Bioxytran, Inc. 617-454-1199 david.platt@bioxytraninc.com Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) is giving its U.S. Air Force Collaborative Combat Aircraft a new name: YFQ-42A Dark Merlin.Dark merlins, deadly falcons known for their black feathers and devouring of other falcons as prey, often collaborate in groups for maximum effect against their targets. The Cornell Lab of Ornithology describes the merlin as a "small, fierce falcon that uses surprise attacks" to bring down its prey in flight. The dark merlin is native to the Pacific Northwest of the United States, often migrating into southern California, where bird spotters routinely report seeing them near the YFQ-42A's manufacturing home in San Diego.The 1962 book "Profiles of the Future" imagined global technological marvels yet to change the world, offering that "any sufficiently advanced technology is indistinguishable from magic." It's no coincidence that the Dark Merlin name also reflects the wizardry of Merlin from Arthurian legend, paying homage to the somewhat supernatural new era of semi-autonomous air combat."Dark merlins are hunting machines, built for speed and aerodynamics," said GA-ASI President David R. Alexander. "They harass other falcons for fun, and they eat what they kill. The name sums up our new uncrewed fighter perfectly."The U.S. Air Force official prefix "Y" denotes that the initial few aircraft are early, production-representative test models, while "F" denotes fighter and "Q" denotes uncrewed aircraft. When aircraft enter production, they drop the "Y" - for example, the YF-16 became the F-16 with the nickname "Fighting Falcon" - and GA-ASI expects its new CCA to become the FQ-42A with the nickname "Dark Merlin."The Dark Merlin has been stacking up milestones and achievements since GA-ASI was selected by the U.S. Air Force in April 2024 to build production-representative flight test articles for the CCA program. In August 2025, YFQ-42A delivered the U.S. Air Force its first successful CCA flight and followed that this month with the service's first CCA flight using mission autonomy software. Between those milestones, GA-ASI has built and flown multiple Dark Merlins, conducting push-button autonomous takeoffs and landings and other accomplishments as the test program continues.YFQ-42A Dark Merlin is a purpose-built CCA platform developed as part of GA-ASI's ongoing investment in next-generation autonomous combat aircraft. The aircraft's modular design enables rapid integration of mission systems. GA-ASI's autonomy architecture, demonstrated through multiple live flight tests, provides the foundation for human-machine teaming in complex combat scenarios.GA-ASI has been building and flying uncrewed jets for nearly two decades, beginning with the company-funded, weaponized MQ-20 Avenger® in 2008. Ongoing company investment in Avenger continues to yield results, as the aircraft routinely serves as a CCA surrogate for advanced autonomy development and testing in both government programs and company-funded research and development. The company's XQ-67A Off-Board Sensing Station jet, developed in collaboration with the U.S. Air Force Research Laboratory, offers a cutting-edge model for autonomous collaborative platforms with advanced airborne sensing and served as a flying prototype for YFQ-42A Dark Merlin.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加州聖地牙哥, 2026年2月23日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司（GA-ASI）為其美國空軍協同作戰飛機賦予新名稱：YFQ-42A「暗影梅林」。暗色隼，這種以黑色羽毛著稱且以其他隼類為食的致命猛禽，常結群行動以對獵物發揮最大殺傷力。康乃爾大學鳥類學實驗室將其描述為「體型嬌小卻凶悍的隼類，擅長突襲」在飛行中擊落獵物。暗色隼原生於美國太平洋西北部，常遷徙至南加州，鳥類觀察者經常在聖地牙哥的YFQ-42A製造基地附近目擊其蹤跡。1962年出版的《未來輪廓》一書預見了尚未改變世界的全球科技奇蹟，提出「任何足夠先進的科技都與魔法無異」的觀點。「暗影遊隼」之名亦非偶然，既呼應亞瑟王傳說中巫師梅林的魔法特質，更向半自主空戰這項近乎超自然的新紀元致敬。通用原子航空系統公司總裁大衛·R·亞歷山大表示：「暗影遊隼是專為速度與空氣動力學打造的狩獵機器。牠們會為樂趣騷擾其他獵鷹，並吞食獵物。此名稱完美概括我們的新型無人戰機特質。」美國空軍官方代號前綴「Y」代表初期少量生產的試驗機型，其中「F」代表戰鬥機，「Q」則代表無人機。當飛機進入量產階段時，代號中的「Y」將被移除——例如YF-16便成為代號「戰隼」的F-16戰鬥機——通用原子航空系統公司預期其新型CCA無人機將正式命名為代號「暗影遊隼」的FQ-42A。自2024年4月通用原子航空系統公司獲美國空軍選中，為CCA計畫建造具量產代表性的飛行測試機型以來，暗影梅林無人機持續累積里程碑與成就。2025年8月，YFQ-42A成功完成美國空軍首架CCA飛行任務；本月更實現該軍種首次搭載任務自主軟體的CCA飛行。在此期間，通用原子航空系統公司持續建造並試飛多架暗黑梅林，在測試計畫推進中完成按鈕式自主起降等多項突破。YFQ-42A暗黑梅林是通用原子公司為持續投資次世代自主作戰飛機而開發的專用CCA平台。其模組化設計可快速整合任務系統，經多次實機飛行測試驗證的自主架構，為複雜戰場中人機協同作戰奠定基礎。GA-ASI近二十年持續研發無人戰機，始於2008年自資研發的武裝型MQ-20復仇者®。該公司對復仇者系列的持續投入成效斐然，該機型現已成為政府計畫與企業研發項目中，用於先進自主系統開發測試的標準化CCA模擬平台。該公司與美國空軍研究實驗室合作研發的XQ-67A機載感測站噴射機，不僅具備先進空中感測能力的自主協作平台尖端模型，更作為YFQ-42A暗影梅林的飛行原型機。關於通用航空系統公司通用原子航空系統公司是全球首屈一指的無人機系統（UAS）製造商。捕食者®系列無人機系統累積飛行時數逾900萬小時，服役超過30年，包含MQ-9A死神®、MQ-1C灰鷹®、MQ-20復仇者®以及MQ-9B天衛者®/海衛者®等機型。該公司致力提供長航時、多任務解決方案，實現持續性戰場感知與快速打擊能力。欲了解更多資訊，請造訪 https://www.ga-asi.com/。GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc. ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月23日 - (亞太商訊 via SeaPRwire.com) - 近日，由斯坦福大學教授、「AI教母」李飛飛創辦的美國世界模型獨角獸World Labs官宣完成新一輪10億美元融資，約合人民幣69.1億元，其中知名CAD廠商Autodesk單獨注資2億美元，折合人民幣13.8億元，英偉達、AMD等科技巨頭及多家投資機構同步跟投。這一重磅消息再次將空間智能、物理AI及世界模型賽道推向資本聚光燈下。在這一全球科技浪潮下，國內物理AI領域的先行者五一視界（6651.HK），其投資價值正逐步凸顯。作為李飛飛深耕AI領域的核心布局，World Labs的融資熱度，本質上是資本對「AI從數字符號走向物理世界」這一趨勢的堅定押注。長期以來，主流AI模型多局限於文本、圖像等數字領域，雖能實現精准的語義理解與生成，卻無法掌握物理世界的基本規律，正如業內所言，這類AI「能言善辯卻手足無措」，而世界模型的出現正是為了彌補這一短板。簡單來說，世界模型就是讓AI構建對三維物理世界的認知，模擬空間關系、物理規律，實現數字世界與物理世界的精准映射，而空間智能與物理AI則是其核心支撐。空間智能是世界模型的基礎，核心是讓AI具備感知、理解三維空間的能力，就像生物通過進化形成的生存本能，能夠預判物體運動軌跡、識別空間布局；物理AI則是連接數字與物理世界的橋梁，區別於傳統數字AI，它能夠模擬重力、摩擦力等物理屬性，實現「感知-預測-行動」的閉環，讓AI從「理論家」變成「實踐者」。World Labs推出的首款產品Marble，便能夠依據圖像或文本提示生成三維世界，正是這種技術邏輯的落地體現。借助此次新籌集到的資金，World Labs 將把重點放在提升該產品在機器人和科學發現等領域的應用能力上，進一步拓展其商業應用場景。此次Autodesk的大額投資，更揭開了世界模型的產業落地邏輯。作為建築、工程領域的CAD軟件巨頭，Autodesk需要打通「設計-模擬-落地」的全流程，而World Labs的世界模型技術恰好能與其3D設計工具深度融合，自動化簡化建模流程，重新定義建築、工程等行業的創作模式。這也意味著，世界模型不再是實驗室裏的技術概念，已進入產業落地階段，而空間智能與物理AI的商業化價值，正被科技巨頭逐步挖掘。作為中國首家登陸資本市場的物理AI企業，五一視界憑借自主研發的51Aes（數字孿生平臺）、51Sim（智駕仿真平臺）、51Earth（數字地球平臺）等核心產品，早已深耕空間智能、數字孿生與物理AI領域，以「克隆地球」為願景，形成了「合成數據-空間智能模型-仿真訓練平臺」的全鏈條物理 AI 閉環生態，與World Labs的技術布局同頻共振。值得注意的是，五一視界已正式納入恒生綜合指數，憑借硬科技屬性與核心技術壁壘，獲得了海內外資本市場的廣泛認可。隨著World Labs引領的世界模型賽道持續升溫，物理AI作為AI下一個十年的核心增長點，市場空間將持續擴大。五一視界深耕行業多年積累的技術優勢、豐富的產業落地經驗與完善的業務生態，使其在國內乃至全球市場都具備顯著競爭力。此次World Labs的10億美元融資，不僅改寫了AI創業公司的估值邏輯，更預示著空間智能、物理AI時代的加速到來。對於投資者而言，五一視界作為國內物理AI領域的標杆企業，其布局契合全球科技發展趨勢，具備清晰的產業落地路徑與長期增長潛力，無疑是把握這一科技風口的核心標的，其投資價值有望在行業爆發期中持續釋放。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com